The Flu Shot Drama at the FDA

What It Covers

The FDA's reversal on reviewing Moderna's mRNA flu shot application reveals deep regulatory instability under Dr. Vinay Prasad, with at least nine pharmaceutical companies reporting sudden policy U-turns affecting drug approvals across vaccines and rare diseases.

Key Questions Answered

• •mRNA Flu Vaccine Timeline: Moderna's mRNA flu shot could reach consumers for the 2026–2027 flu season, with the FDA's decision deadline set for August 5. The technology promises faster vaccine production than the current six-month global strain-guessing process used annually.
• •Regulatory Goalpost Shifting: The FDA, under Dr. Vinay Prasad, now requires randomized controlled trials instead of antibody-response studies for vaccine approval — a costlier, more time-consuming standard that contradicts prior agreements made with Moderna before clinical trials began.
• •Rare Disease Drug Risk: Nine companies have publicly reported sudden FDA U-turns on previously approved trial designs. Pierre Fabre Pharmaceuticals received a rejection citing trial methodology concerns — the same single-arm trial approach Prasad publicly praised at a conference just days later.
• •FDA Institutional Instability: The FDA's drug division has cycled through five leaders in one year, losing significant scientific staff through turnover. Pharmaceutical companies investing millions in clinical trials depend on regulatory predictability; current volatility raises financial risk across the entire drug development pipeline.